Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13046-021-02030-5
Keywords
Primary liver cancer; Cellular based immunotherapy; Lymphoid cell; Myeloid cell; Combined immunotherapy
Categories
Funding
- National Natural Science Foundation of China [82002539]
- Yangfan Project of Shanghai Science and Technology Commission [20YF1443300]
- Natural Science Foundation of Shanghai [19ZR1447700]
- Health System Innovation Project of Shanghai Putuo Science and Technology Commission [PTKWWS201801, PTKWWS201903]
- WBN Hepatology Research Fund of China Hepatitis Prevention and Treatment Foundation [CFHPC2019031]
Ask authors/readers for more resources
Cellular based immunotherapy, with its natural advantages in PLC treatment by involving both lymphoid and myeloid cells, is promising. However, there are still obstacles and challenges in PLC treatment that need to be addressed through comprehensive immunotherapeutic approaches.
Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies. For most malignancies, including PLC, immune cells play crucial roles in regulating tumor microenvironments and specifically recognizing tumor cells. Therefore, cellular based immunotherapy has its instinctive advantages in PLC therapy as a novel therapeutic strategy. From the active and passive immune perspectives, we introduced the cellular based immunotherapies for PLC in this review, covering both the lymphoid and myeloid cells. Then we briefly review the combined cellular immunotherapeutic approaches and the existing obstacles for PLC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available